Thu, December 13, 2012
Wed, December 12, 2012
Tue, December 11, 2012
Mon, December 10, 2012
Sun, December 9, 2012
Sat, December 8, 2012
Fri, December 7, 2012
Thu, December 6, 2012
Wed, December 5, 2012
Tue, December 4, 2012
Mon, December 3, 2012
Sun, December 2, 2012
Sat, December 1, 2012
Fri, November 30, 2012
Thu, November 29, 2012
Wed, November 28, 2012
Tue, November 27, 2012
Mon, November 26, 2012
Sun, November 25, 2012
Fri, November 23, 2012
Thu, November 22, 2012
Wed, November 21, 2012
Tue, November 20, 2012
Mon, November 19, 2012
Sat, November 17, 2012
Fri, November 16, 2012

PDL BioPharma Announces Resignation of Chief Financial Officer


//health-fitness.news-articles.net/content/2012/ .. nces-resignation-of-chief-financial-officer.html
Published in Health and Fitness on Monday, December 3rd 2012 at 13:15 GMT by Market Wire   Print publication without navigation


PDL BioPharma Announces Resignation of Chief Financial Officer -- INCLINE VILLAGE, Nev., Dec. 3, 2012 /PRNewswire/ --

INCLINE VILLAGE, Nev., Dec. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: [ PDLI ]) today announced that Bruce Tomlinson has resigned his position as vice president and chief financial officer of PDL due to personal reasons.  His resignation is effective as of November 30, 2012.  The company will begin a search for a new CFO.

(Logo: [ http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ])

"On behalf of the team at PDL, I would like to thank Bruce for his contributions and insights and wish him well in his future endeavors," stated John McLaughlin, president and chief executive officer of PDL.

"In recent months, PDL completed three transactions related to its campaign to bring in new revenue generating assets, and it has been a pleasure to be a part of PDL and its recent accomplishments," stated Mr. Tomlinson.  "I wish PDL, its team and its shareholders continued success."

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit [ www.pdl.com ].

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.  

SOURCE PDL BioPharma, Inc.



RELATED LINKS
[ http://www.pdl.com ]

Publication Contributing Sources